Study title: An Extension of Trial 1033US/0006 to Assess the Safety, Tolerability and Efficacy of Anastrozole (ZD1033, Arimidex™) in the Treatment of Gynecomastia in Pubertal Boys Given Placebo in Trial 1033US/0006 and to Conduct a Long-Term Safety Follow-Up of Non-Responding Subjects Given Anastrozole in the Previous Trial
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Endocrine System Diseases | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: ANASTROZOLE | |||||
ATC code: L02BG03 | |||||
Document link: 1033US0016 CSR Synopsis.pdf | |||||
Document date: 2011-08-15 | |||||
Study number: 1033US0016 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |